Sulfonylureas, the oldest class of medications for the treatment of type 2 diabetes, akin to KCl treatment, induce membrane depolarization and insulin secretion by binding to the sulfonylurea receptor subunit on ATP-sensitive potassium channels (Costello et al, 2024). The gene discussed is INS; the disease is type 2 diabetes mellitus.